ストックスクリーナーアプリを入手
566.80
0.03%
-0.19
アフターアワーズ：
564.00
-2.80
-0.49%
前日終値:
$566.99
開ける：
$566.99
24時間の取引高:
402.31K
Relative Volume:
0.79
時価総額：
$24.06B
収益：
$3.17B
当期純損益:
$1.29B
株価収益率:
20.92
EPS:
27.0947
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
-2.57%
1か月 パフォーマンス:
-3.67%
6か月 パフォーマンス:
+18.94%
1年 パフォーマンス:
+85.65%
1日の値動き範囲:
$560.23
$572.45
1週間の範囲:
$560.23
$584.71
52週間の値動き範囲:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
566.80 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
16.58 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.20 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.92 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics Corp at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.4m in stock - Investing.com Nigeria
United Therapeutics (UTHR) Reports TETON Study Results on Nebuli - GuruFocus
United Therapeutics’ Tyvaso meets primary endpoint in IPF trial - Investing.com
Inhaled Tyvaso preserves lung function, cuts IPF risks in trial - Stock Titan
United Therapeutics (UTHR) Remains a Key Holding for Renaissance Technologies - GuruFocus
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics (UTHR) Reports Positive Ralinepag Results in Pulmonary Hypertension Study - GuruFocus
Baidu, Brady And 3 Stocks To Watch Heading Into Monday - Benzinga
Experimental PAH pill ralinepag cuts worsening risk 55% in Phase 3 - Stock Titan
Leuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock (US9113631090): FDA clears first UHeart xenotransplantation trial - AD HOC NEWS
United Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for Lutherans - MarketBeat
United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial - marketscreener.com
United Therapeutics stock (US9113631090): fresh data push at ATS 2026 keeps pipeline in focus - AD HOC NEWS
United Therapeutics (UTHR) Receives FDA Approval for UHeart Clin - GuruFocus
FDA clears first human trial of pig-derived transplant heart - Stock Titan
United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares - MarketBeat
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Varda Space and United Therapeutics to test drugs in space microgravity - Новости GxP
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock By Investing.com - Investing.com Canada
Martine Rothblatt, CEO, sells $5.5m in United Therapeutics stock - Investing.com
Pacer Advisors Inc. Trims Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Ameritas Advisory Services LLC Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
Varda Space, United Therapeutics to test lung drugs in orbit - qz.com
United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
United Therapeutics director Mesa Nilda sells $150,139 in stock By Investing.com - Investing.com Australia
Insider Sell: Nilda Mesa Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics director Mesa Nilda sells $150,139 in stock - Investing.com
Varda Space, United Therapeutics partner on drug development By Investing.com - Investing.com India
United Therapeutics (UTHR) Partners with Varda Space Industries for Innovative Drug Development - GuruFocus
Varda and United Therapeutics Partner to Crystallize Protein in Space for Rare Lung Disease Therapies - geneonline.com
Varda Space, United Therapeutics partner on drug development - Investing.com India
Could this be the moment that drug manufacturing takes off in orbit? - Ars Technica
Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease - ChartMill
United Therapeutics Corp (UTHR) News, Articles, Events & Latest Updates - Stocktwits
United Therapeutics CFO James Edgemond sells $5.7m in stock By Investing.com - Investing.com Nigeria
United Therapeutics CFO James Edgemond sells $5.7m in stock - Investing.com India
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - Quantisnow
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference - ChartMill
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
2.00%
1.54%
大文字化:
|
ボリューム (24 時間):